Interference No. 103,625
PheThrProTyrAlaProGluProGlySerThrCysArg (sequence 1a)
AlaPheThrProTyrAlaProGluProGlySerThrCysArg
ValAlaPheThrProTyrAlaProGluProGlySerThrCysArg
GlnValAlaPheThrProTyrAlaProGluProGlySerThrCysArg
AlaGlnValAlaPheThrProTyrAlaProGluProGlySerThrCysArg (sequence 3b)
ProAlaGlnValAlaPheThrProTyrAlaProGluProGlySerThrCysArg (sequence 2b)
LeuProAlaGlnValAlaPheThrProTyrAlaProGluProGlySerThrCysArg(sequence 2a and 1b)
The TNF"-binding protein in the ‘089 application was said to be isolated
o
from the urine of patients with fever ($38 C) or from ascites fluid from a patient with ovarian
sarcoma (P000107-P000108) and concentrated by ultrafiltration or reverse osmosis, and
then the retentate was purified by ion exchange chromatography (P000107, page 2, lines
4-5, page 3, line 5 et seq).
Opinion
LeMaire have the burden to establish by a preponderance of the evidence
that their earlier filed applications satisfy 35 U.S.C. § 112, first paragraph. Kubota v.
Shibuya, 999 F.2d 517, 27 USPQ2d 1418 (Fed. Cir. 1993). In our view, the German
applications(‘072 and ‘089) do not reasonably convey to those skilled in the art that
LeMaire had possession of the proteins having the N terminus amino acid sequences
or the process of obtaining the proteins of LeMaire claims 1-3. Vas-Cath, 935 F.2d at
1563, 19 USPQ2d at 1116; Forssmann v. Matsuo, 23 USPQ2d 1548, 1551 (Bd. Pat. App.
13
Page: Previous 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next
Last modified: November 3, 2007